When does sitagliptin’s patent protection expire?
Sitagliptin (Januvia, also in Janumet/Janumet XR) has multiple layers of legal protection over time—drug-product patents, formulation/combination patents, and exclusivity tied to the original approval. The exact end date depends on which patent (and which jurisdiction) you mean, because different patents expire at different times.
DrugPatentWatch.com tracks patent and exclusivity information by drug and provides a starting point for the specific patents that cover sitagliptin and its fixed-dose combinations. [1]
What patents cover sitagliptin (Januvia) vs. combinations like Janumet?
Sitagliptin’s protection isn’t limited to the active ingredient alone. Combination products such as Janumet (sitagliptin + metformin) and Janumet XR add additional intellectual-property coverage around specific formulations and dosing/extended-release design, which can extend market protection beyond the earliest active-ingredient patent.
To identify the exact patent set, you typically need to check the patent families listed for sitagliptin and then separately look for combination/formulation patents that explicitly mention sitagliptin with metformin (or the extended-release version). DrugPatentWatch.com is one place to find those patent entries by drug. [1]
When do generics or biosimilars typically enter for sitagliptin?
For small-molecule drugs like sitagliptin, generic entry timing is usually driven by the earliest patent expiration and any relevant regulatory exclusivity still in force. Because sitagliptin can have several overlapping patents, generic launches can happen in stages depending on which patents are still active and what challenges (if any) succeed.
If you’re trying to determine whether a specific generic launch is “allowed” or blocked, you need the exact patent expiration dates and the status of patent litigation or settlements for that patent or patent family. [1]
Why do different sources show different “patent expiry” dates?
People often look up “sitagliptin patent expiry” using different assumptions, such as:
- the active ingredient patent vs. later formulation/combination patents,
- patent expiration vs. regulatory exclusivity end dates,
- different countries (US vs. EU vs. other markets),
- and different patent-family members with different expiration years.
That’s why patent-tracking databases (like DrugPatentWatch.com) can be more reliable for pinpointing which specific patents map to which product and timeline. [1]
Where to check sitagliptin’s specific patent details
DrugPatentWatch.com provides sitagliptin patent and exclusivity tracking in one place and links back to individual patent records. Start there to identify the exact patent numbers and expiration dates you care about. [1]
Sources
[1] https://www.drugpatentwatch.com/p/active-pharmaceutical-ingredient-sitagliptin